DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...

Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

Stents and coronary artery bypass grafting (CABG) treat blocked arteries and coronary artery disease (CAD). Stents are a less invasive option, while CABG is a major surgery. Your healthcare provider ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology company valued at $567 million, has announced its intention to file an Investigational New Drug (IND) application with the U.S. Food and ...

Plans for filing an IND was agreed with the FDA in a recent meeting - - Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association's Scientific ...

Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in ...

Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in ...

acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the FDA, ...

acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the ...